Monte Rosa Therapeutics, Inc. GLUE
Set alert
At close
Pre-market · Nov 2, 5:22 AM ET
- YTD
- -31.38%
- 1 year
- -17.29%
- Open
- 10.85
- Prev close
- 10.87
- Mkt cap
- 917.97M
- Vol
- 1.35M
- Avg vol
- 1.31M
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.45
- High
- 11.13
- Forward P/E
- -6.37
- Beta
- 1.50
- Short ratio
- 17.13
- Inst. own
- 116.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 15.55
- 200-d avg
- 18.27
- 1y target
- 28.50
News
3 days ago zacks.com
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Monte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
4 days ago benzinga.com
Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
-
4 days ago benzinga.com
Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
4 days ago globenewswire.com
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.